CD28 and rheumatoid arthritis: However, despite the clear role of the CTLA-4/CD28 pathway in the RA immune response, many patients do not respond adequately to Abatacept, indicating disease biology driven by alternative inflammatory pathways (possibly including other checkpoint mechanisms) and highlight the critical unmet need for the development of individualised targeted therapy in RA.